Increasing Patient Adherence to Schizophrenia Treatment Regimen
Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, explain how to increase patient adherence to treatment and address the stigma associated with schizophrenia even in the family of the patient.
Schizophrenia Relapse: Diagnosis, Prevention, and Impact
Henry Nasrallah, MD, examines schizophrenia relapse, specifically how to diagnose and prevent it before further damage has transpired in the patient’s brain.
New Labeling Requirements Put Forth by the FDA for Opioids
Theresa Mallick-Searle, MS, RN-BC, ANP-BC, shares her perspective on the new labeling requirements put forth by the FDA for opioids in regards to naloxone.
Risks for Accidental Opioid Overdose Seen in the Community
Joshua Lynch, DO, EMT-P, FAAEM, FACEP, highlight risks he has seen in the community for unintended users as well as patients for accidental opioid overdose.
Lawrence F. Eichenfield, MD; Jeffrey M. Bienstock, MD, FAAP; Peter A. Lio, MD; and Elizabeth A. Swanson, MD, discuss whether children outgrow atopic dermatitis and advice for the management of disease.
Optimizing Care for ADHD During COVID-19
Optimizing care and managing challenges for patients with ADHD during the COVID-19 pandemic and advice for clinicians educating patients and families on disease management.
Addressing Drug Holidays for ADHD Medication
Rakesh Jain, MD, MPH, shares his thoughts on whether drug holidays are appropriate for children taking medication for ADHD.
Approaching ADHD Treatment Selection in Children and Adults
Rakesh Jain, MD, MPH, considers the evidence-based recommended hierarchy in the choice of medications for the treatment of pediatric and adult ADHD.
FDA-Approved Medications for ADHD
Andrew J. Cutler, MD, reviews currently available stimulants and nonstimulants as well as their safety and efficacy for the treatment of ADHD.
Benefits of a Multimodal Treatment Approach to ADHD
Rakesh Jain, MD, MPH, shares his thoughts on the importance of combining pharmacological and non-pharmacological treatments for the management of ADHD.
Non-Pharmacological Therapy in ADHD
Andrew J. Cutler, MD, discusses the benefits of cognitive behavior therapy (CBT), exercise, and family therapy for the management of ADHD.
Updates in Diagnostic and Treatment Guidelines for ADHD
Updates in the AAP (American Academy of Pediatrics) and SDBP (Society for Developmental and Behavioral Pediatrics) guidelines for the assessment, evaluation, and treatment of ADHD in children and adolescents.
Use of Developmental Screening Tools to Identify Early Signs of SMA
Standardized screening is used by support staff to assess developmental milestones to assist in the recognition of spinal muscular atrophy (SMA).
Psychiatric Teams: Treating Schizophrenia Comorbidities
Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, discuss the challenges and unmet needs psychiatrists and their teams face when treating patients with schizophrenia and their multiple comorbidities.
Opioid Crisis Misconceptions and Unintended Consequences
Jeffrey Bratberg, PharmD, FAPhA, leads discussion tackling common opioid-related misconceptions as well as unintended consequences of the opioid crisis.
Current State of the Opioid Crisis: Multifaceted Point of View
Jeremy Adler, DMSc, PA-C, DFAAPA, leads discussion on elements that negatively impacts the quality of care for patients requiring pain management.
Impact of ADHD on Quality of Life
Rakesh Jain, MD, MPH, comments on factors pre-disposing children and adults to ADHD and the impact of disease on patients’ and caregivers’ quality of life (QoL).